Acimtamig
- Generic Name
- Acimtamig
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2738880-26-5
- Unique Ingredient Identifier
- ND470TT8Y3
- Background
Acimtamig is a tetravalent bispecific chimeric anti-human CD30 x anti-human CD16A recombinant antibody construct.
- Associated Conditions
- -
- Associated Therapies
- -
Affimed's Cancer Drug Achieves 86% Response Rate in Advanced Lymphoma Clinical Trial
Affimed's acimtamig and AlloNK® combination showed 86% overall response and 55% complete response in 22 heavily pretreated R/R cHL patients, with a well-managed safety profile.
FDA RMAT status for Affimed and Artiva's lymphoma combo therapy
FDA grants RMAT status to Affimed and Artiva’s lymphoma combo therapy, based on 83.3% overall response rate and 50% complete response rate in R/R HL patients, with potential for accelerated approval and priority review.
FDA grants RMAT to Affimed and Artiva's lymphoma therapy
FDA grants RMAT designation to Affimed and Artiva's lymphoma combo therapy, involving AlloNK (AB101) and acimtamig (AFM13), for treating R/R HL. Early LuminICE-203 trial data shows 83.3% overall response rate and 50% complete response rate with a well-managed safety profile. The RMAT designation accelerates development and offers potential for accelerated approval and priority review.
Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine
FDA grants RMAT designation to Affimed's acimtamig and Artiva's AlloNK® for relapsed/refractory Hodgkin Lymphoma, based on 83.3% overall response rate and 50% complete response rate in early efficacy data.
Affimed Announces Acimtamig and AlloNK® Combination Granted RMAT Designation by FDA for Relapsed/Refractory Hodgkin Lymphoma
The FDA granted RMAT designation to Affimed's innate cell engager acimtamig and Artiva's AlloNK® for relapsed/refractory Hodgkin Lymphoma, based on an 83.3% overall response rate and 50% complete response rate in early efficacy data, with a well-managed safety profile.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath